Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
As of today (2026-07-17), Enzymatica AB's 9-Day RSI is 42.96.
The industry rank for Enzymatica AB's 9-Day RSI or its related term are showing as below:
FRA:EN9's 9-Day RSI is ranked better than 75.5% of 1049
companies
in the Drug Manufacturers industry
Industry Median: 53.15
vs FRA:EN9: 42.96
Enzymatica AB (FRA:EN9) 9-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Enzymatica AB 9-Day RSI Related Terms
FRA:EN9 vs ZTS, UTHR: 9-Day RSI Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Enzymatica AB's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Enzymatica AB 9-Day RSI vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Enzymatica AB's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where Enzymatica AB's 9-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enzymatica AB (FRA:EN9) has a 9-Day RSI of 42.96 as of Jul. 17, 2026. According to the industry distribution chart, Enzymatica AB ranks #257 out of 1049 companies in the Drug Manufacturers industry, placing it in the top 24.5%.
Is Enzymatica AB's 9-Day RSI too high?
Enzymatica AB's current 9-Day RSI is 42.96. The Drug Manufacturers industry median 9-Day RSI is 53.15. Enzymatica AB's value of 42.96 is 19.2% below this industry median. Based on the distribution chart, Enzymatica AB ranks #257 out of 1049 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Enzymatica AB has a GF Score™ of 43/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Enzymatica AB's 9-Day RSI compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Enzymatica AB ranks #257 out of 1049 companies for 9-Day RSI. This places Enzymatica AB in the top 25% of its industry — outperforming the majority of peers. The industry median 9-Day RSI is 53.15. Enzymatica AB's value of 42.96 is 19.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Drug Manufacturers company?
The median 9-Day RSI among Drug Manufacturers companies is 53.15, based on 1,049 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Enzymatica AB's current 9-Day RSI of 42.96 is 19.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median 9-Day RSI is 53.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Enzymatica AB's current 9-Day RSI is 42.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Enzymatica AB stock overvalued right now?
Based on GuruFocus' analysis, Enzymatica AB (FRA:EN9) is currently considered Modestly Overvalued. The stock's GF Value™ is €0.16, compared to a current price of €0.18 — trading 12.8% above its estimated fair value. The current 9-Day RSI is 42.96 and 19.2% below the Drug Manufacturers industry median of 53.15. Enzymatica AB's overall GF Score™ is 43/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For Enzymatica AB (FRA:EN9), the current 9-Day RSI is 42.96 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Enzymatica AB (FRA:EN9) Overvalued in 2026?
Based on GuruFocus' analysis, Enzymatica AB stock appears to be overvalued.
The current stock price of €0.18 is trading 12.8% above its estimated GF Value™ of €0.16.
GuruFocus considers Enzymatica AB to be Modestly Overvalued.
Key valuation signals for FRA:EN9:
9-Day RSI: 42.96
GF Value™: €0.16 vs. price of €0.18 (12.8% above fair value)
Industry Position: 19.2% below the Drug Manufacturers median (#257 of 1049)
No single metric tells the full story. See the FRA:EN9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Enzymatica AB is a life science company that develops and sells medical devices against infectious diseases, based on a barrier technology, which includes marine enzymes. Its product ColdZyme Mouth Spray prevents cold and reduces disease period.
43GF Score
Get the complete analysis for FRA:EN9
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:EN9 has been successfully added to your 
